» Articles » PMID: 11879261

Onset and Duration of Action of Sildenafil for the Treatment of Erectile Dysfunction

Overview
Specialty Pharmacology
Date 2002 Mar 7
PMID 11879261
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To determine the onset and duration of action of sildenafil in patients with erectile dysfunction (ED).

Methods: Two randomised, double-blind, placebo-controlled, two-way crossover studies were conducted in men with ED of no known organic cause. Study I: The time to onset of erections after sildenafil (50 mg) or placebo dosing following visual sexual stimulation (VSS) was assessed in 17 patients. Patients not achieving >60% penile rigidity by 70 min postdose as measured by a RigiScan(R) monitoring device were assigned an onset time of 70 min. Study II: The duration of grade 3 (hard enough for penetration) and grade 4 (fully hard) erections, determined by self-assessment during 60 min of VSS starting 2 and 4 h after sildenafil (100 mg) or placebo dosing, was measured in 16 patients.

Results: Study I: The median time (range) to onset of erections was 27 min (in a range of 12--70) after receiving sildenafil 50 mg. In the sildenafil group, 71% of patients experienced onset of erections within 30 min of dosing, and 82% responded within 45 min. Of the patients who achieved >60% penile rigidity after sildenafil, 86% had done so by 30 min after dosing. Study II: When VSS began 2 h postdose, the median duration of grade 3 or 4 erections was 19.5 min (0--55) for sildenafil vs 0 min (0--23) for placebo. When VSS began 4 h postdose, the median duration was 5 min (0--45) for sildenafil compared with 0 min for placebo (0--27).

Conclusions: Sildenafil is an effective oral treatment for ED that produces a penetrative erection as early as 12 min and for most patients, within 30 min after dosing, and a duration of action lasting at least 4 h.

Citing Articles

Revolutionising Neurological Therapeutics: Investigating Drug Repurposing Strategies.

Attri M, Raghav A, Sinha J CNS Neurol Disord Drug Targets. 2024; 24(2):115-131.

PMID: 39323347 DOI: 10.2174/0118715273329531240911075309.


The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders.

Degjoni A, Campolo F, Stefanini L, Venneri M J Thromb Haemost. 2022; 20(11):2465-2474.

PMID: 35950928 PMC: 9805178. DOI: 10.1111/jth.15844.


Hotspots and frontiers in pulmonary arterial hypertension research: a bibliometric and visualization analysis from 2011 to 2020.

He Z, Dai L, Zuo Y, Chen Y, Wang H, Zeng H Bioengineered. 2022; 13(6):14667-14680.

PMID: 35880647 PMC: 9342150. DOI: 10.1080/21655979.2022.2100064.


Phosphodiesterase Type 5 Inhibitors Greatly Affect Physicochemical Properties of Model Lipid Membranes.

Zakharova A, Efimova S, Ostroumova O Membranes (Basel). 2021; 11(11).

PMID: 34832122 PMC: 8622654. DOI: 10.3390/membranes11110893.


Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.

Tang P, Zheng X, Hu X, Yang C, Chen Z, Qian J Drug Des Devel Ther. 2020; 14:5129-5141.

PMID: 33262574 PMC: 7699448. DOI: 10.2147/DDDT.S268796.


References
1.
Conti C, Pepine C, Sweeney M . Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol. 1999; 83(5A):29C-34C. DOI: 10.1016/s0002-9149(99)00045-4. View

2.
Rendell M, Rajfer J, Wicker P, Smith M . Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999; 281(5):421-6. DOI: 10.1001/jama.281.5.421. View

3.
Montorsi F, McDermott T, Morgan R, Olsson A, Schultz A, Kirkeby H . Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology. 1999; 53(5):1011-8. DOI: 10.1016/s0090-4295(98)00643-8. View

4.
Giuliano F, Hultling C, El Masry W, Smith M, Osterloh I, Orr M . Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. Ann Neurol. 1999; 46(1):15-21. DOI: 10.1002/1531-8249(199907)46:1<15::aid-ana5>3.0.co;2-u. View

5.
Rajfer J, Aronson W, Bush P, Dorey F, Ignarro L . Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992; 326(2):90-4. DOI: 10.1056/NEJM199201093260203. View